What an exciting week in Northern California! Can you believe what they announced? How do you think it will change the industry? Just when we thought they were done innovating… BAM! They bring this to the table!

I’m talking about the new Apple iPhone and iOS release right? WRONG! I’m talking about the next generation of AdverseEvents Explorer!

Depending how closely you follow AdverseEvents’ communications (and how good our Marketing Department has been in getting you to click on them!), you may have seen that just this week we rolled out a significantly enhanced version of our software platform, AdverseEvents Explorer.

Along with several design changes and user experience upgrades, we’ve added new datasets that we expect to revolutionize how FDA Adverse Event Reporting System (FAERS) data is used by non-pharmacovigilance experts.

Some of the new enhancements include:

  • Adverse event incidence estimates for 800+ drugs, from 2011-2013 calculated using patient population numbers provided by our partner, EvaluatePharma®
  •  
  • On/Off Label designation for every drug/side effect combination for drugs where a RxScore has been assigned
  •  
  • Label Section descriptions (adverse reactions, clinical trials, black box warnings, etc…)
  •  
  • RxSignal designation as (RxSignal eligible side effect + off label + ROR > 2.0)
  •  
  • IME Serious and FDA DME list designations
  •  
  • Removal / Filtering of disease related adverse events
  •  
  • Dynamic sorting and filtering options to ensure you only see the data you need

Don’t think that these are as game changing as what Apple announced? Sign up for a trial of AdverseEvents Explorer and let us change your mind.



Jim Davis

Jim Davis

Executive Vice President

Jim Davis LinkedinJim Davis Twitter

 

Jim Davis

Written by Jim Davis

As Executive Vice President, Jim is responsible for the commercialization strategy for Advera Health Analytics.